Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

ClinicalTrials.gov ID: NCT04317534

Public ClinicalTrials.gov record NCT04317534. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153

Study identification

NCT ID: NCT04317534
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Greg Durm, MD; Other
Enrollment: 244 participants

Conditions and interventions

Conditions

NSCLC, Stage I

Interventions

Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 4, 2020
Primary completion: Apr 7, 2027
Completion: Apr 7, 2028
Last update posted: May 4, 2026

2020 – 2028

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
Moffit Cancer Center	Tampa	Florida	33612	Recruiting
University of Illinois Cancer Center	Chicago	Illinois	60612	Recruiting
Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	46202	Recruiting
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	Recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68198	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	Recruiting
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
Providence Health & Services - Oregon	Portland	Oregon	97213	Recruiting
Penn State Cancer Institute	Hershey	Pennsylvania	17033	Recruiting
University of Virginia Health System	Charlottesville	Virginia	22908	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23298	Recruiting
Univeristy of Wisconsin	Madison	Wisconsin	53705	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04317534, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 4, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04317534 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →